Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 125,990

Document Document Title
WO/2017/172811A1
The disclosure provides new, stable, pharmaceutically acceptable co-crystal forms of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-h exahydro-1H,7H-pyrido[3´ 4´:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together w...  
WO/2017/167417A1
The present invention relates to a composition comprising choline for use in promoting, supporting or optimizing one or more of the following: (i) de novo myelination; (ii) brain structure; (iii) brain connectivity; (iv) intellectual pot...  
WO/2017/173049A1
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.  
WO/2017/172771A2
A method of treating an IL-12/23 -related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4...  
WO/2017/170926A1
The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This i...  
WO/2017/167415A1
The present invention relates to a composition comprising one or more fatty acid derivatives for use in promoting, supporting or optimizing one or more of the following: (i) de novo myelination; (ii) brain structure; (iii) brain connecti...  
WO/2017/173442A1
Topical compositions are provided containing one or more agents to treat and/or prevent pain. The compositions of the invention can be topically administered to a subject to treat pain, for example, neuropathic pain.  
WO/2017/168137A1
There is provided herein a compound of formula I (I) or a tautomer and/or pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a neurodegenerative disorder, wherein X, Y, Z, R1, R2 and n have meanings as pr...  
WO/2017/169966A1
[Problem] The purpose of the present invention is to provide a strain of Bifidobacteria having a high serotonin-secretion-promoting ability, and a food and/or beverage containing a treated form of the Bifidobacterium. [Solution] The inve...  
WO/2017/173048A1
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin- related disorders.  
WO/2017/168244A1
The present application relates to a method of treating Parkinson's disease by administering a mouth-dissolving composition of N-propargylamine derivative, such as rasagiline or a pharmaceutically-acceptable salt thereof.  
WO/2017/167416A1
The present invention relates to a composition comprising a phospholipid or a metabolic precursor or metabolite thereof, or a mixture thereof, for use in promoting, supporting or optimizing one or more of the following: (i) de novo myeli...  
WO/2017/172914A1
The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In p...  
WO/2017/171053A1
The present invention provides a pharmaceutical composition for the treatment or prevention of synucleinopathy, the pharmaceutical composition including a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.  
WO/2017/173052A1
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.  
WO/2017/170765A1
Provided are: a novel nitrogen-containing heterocyclic compound, which has an aldosterone synthase-inhibiting activity and, therefore, is useful for preventing and/or treating various diseases or symptoms associated with aldosterone and/...  
WO/2017/173031A1
Compositions for oral administration and processes of preparing the same are described. In particular, compositions in the form of bilayer tablets including B vitamins for modified delivery are described. The bilayer multi-B vitamin tabl...  
WO/2017/167250A1
Provides an artificial enzyme obtained by improving upon a sequence of a natural nicotine dehydrogenase, wherein the improvement comprises replacing at least one amino acid hindering product release with an amino acid with a smaller side...  
WO/2017/170924A1
The purpose of the present invention is to provide a peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing said peptide, and a preventive or alleviative pharmaceutical composition. This i...  
WO/2017/171100A1
The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyo...  
WO/2017/170830A1
Provided is a compound having an MAGL-inhibiting effect, and anticipated to be useful as a prophylactic or therapeutic agent for neurodegenerative diseases (for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, amy...  
WO/2017/167419A1
The present invention relates to a composition comprising one or more mineral nutrients selected from iron, zinc, calcium, phosphorus, copper, magnesium, iodine, manganese, chloride, potassium, sodium, selenium, chromium, and combination...  
WO/2017/173451A1
Methods for treating neurodegenerative diseases that can include targeting TANK Binding Kinase 1 (TBK1), I kappa B kinase (IKK), Signal Transducer and Activator of Transcription 1 (STAT1), or Janus Kinase 1 or Janus Kinase 2 (Jak1/2).  
WO/2017/172757A1
Described are compounds and compositions for use in methods for reducing the rate of accumulation of amyloid plaques in a subject by administering a 5-HT2A serotonin receptor inverse agonist or antagonist, or pharmaceutically acceptable ...  
WO/2017/167899A1
The present invention relates to a composition comprising one or more fatty acid derivatives for use in promoting, supporting or optimizing one or more of the following: (i) de novo myelination; (ii) brain structure; (iii) brain connecti...  
WO/2017/167898A2
The present invention relates to a composition comprising at least one vitamin, for use in promoting, supporting or optimizing one or more of the following: (i) de novo myelination; (ii)brain structure; (iii)brain connectivity; (iv)intel...  
WO/2017/171563A1
Improving the cognitive function of an animal by providing a composition containing beta-casein, wherein at least 75% by weight of the beta-casein is a beta-casein variant that does not produce BCM-7 on digestion in the gut of the animal.  
WO/2017/167180A1
The present invention provides a vortioxetine pamoic acid salt, which includes a crystal form, a solvate or an amorphous substance of the vortioxetine pamoic acid salt. The present invention provides a preparation method and use of the v...  
WO/2017/167897A1
The present invention relates to a composition comprising a phospholipid or a metabolic precursor or metabolite thereof, or a mixture thereof, for use in promoting, supporting or optimizing one or more of the following: (i) de novo myeli...  
WO/2017/167896A1
The present invention relates to a composition comprising one or more mineral nutrients selected from iron, zinc, calcium, phosphorus, copper, magnesium, iodine, manganese, chloride, potassium, sodium, selenium, chromium, and combination...  
WO/2017/167420A1
The present invention relates to a composition comprising at least one vitamin, for use in promoting, supporting or optimizing one or more of the following: (i) de novo myelination; (ii) brain structure; (iii) brain connectivity; (iv) in...  
WO/2017/168138A1
The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Webe...  
WO/2017/171594A1
The present disclosure relates to the use of negative allosteric modulators (NAMs) of the metabotropic glutamate receptor 5 (mGluR5) in the treatment of a mature brain damage, such as damage after stroke.  
WO/2017/165845A1
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxyb...  
WO/2017/164084A1
Provided is a patch preparation which has a misuse prevention performance. The patch preparation comprises a support and a plaster, wherein the plaster contains 2-35 wt% of a solvent which has a vapor pressure of 1 kPa or greater at 20oC...  
WO/2017/165877A1
Disclosed is a method of treating Psychotic Depression, Suicidal Ideation, Disruptive Mood Dysregulation Disorder, Persistent Depressive Disorder (Dysthymia), Premenstrual Dysphoric Disorder, Substance/Medication-Induced Depressive Disor...  
WO/2017/164331A1
Provided is a low-cytotoxicity composition that can be applied to a drug delivery system enabling passage through the blood-brain barrier. A nanoparticle composition comprises nanoparticles to the surface of which a first substance and s...  
WO/2017/161402A1
A formulation and a method for treating, preventing, ameliorating or alleviating in a patient the symptoms of hangover, or of veisalgia, associated with a bout of excessive alcohol consumption are disclosed. More specifically, a formulat...  
WO/2017/162884A1
The present invention relates to a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Ratin...  
WO/2017/164230A1
The present invention provides a phosphorylated SARM1 (Sterile alpha and TIR motif-containing protein 1) in which at least one Ser residue selected from the group consisting of position 54, position 548, and position 622 of SARM1 is phos...  
WO/2017/162870A1
Methods for improving active movement capacity in a subject experiencing muscle impaired or abnormal activity, and software products and computer systems for implementing such methods. A subject having impaired active movement capacity i...  
WO/2017/164173A1
Provided is a novel compound which has an excellent Aβ aggregation-inhibiting activity and is useful as a medicine. An imidazole compound represented by general formula (1) (wherein A, B and C may be the same as or different from one an...  
WO/2017/164172A1
Provided are a compound that is bioapplicable and amyloid-selective, and is useful as an amyloid oxidation catalyst applicable not only to aβ peptides but to other amyloids as well, and a preventive/therapeutic agent for amyloid-related...  
WO/2017/162168A1
The present invention relates to a salt form of (R)-methyl-2-(3-aminopiperidin-1-yl)-3-(2-cyanobenzyl)-4-car bonyl-3,4-dihydrothiophene[3,2-d]pyrimidine-6-carboxylic acid and a preparation method for the salt form. Also disclosed is a ph...  
WO/2017/162830A1
A process for preparing a modified heat-treated platelet pellet lysate, said process comprising the steps of: a) Providing a platelet pellet lysate, b) Heat-treating the platelet pellet lysate at a temperature of 55°C to 65°C during 20...  
WO/2017/165755A1
The invention relates to particular substituted fluorinated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositi...  
WO/2017/165635A1
A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is ...  
WO/2017/165806A1
Disclosed herein are compositions and methods for treating neuropathy, embodiments, HSV vectors are provided comprising nucleic acid molecules encoding neurotrophins, such as neurotrophin 3 (NT3).  
WO/2017/163101A1
Embodiments of the present invention disclose formulations comprising NAD for reducing sugar craving and methods of making and using the same. Embodiments of the invention also discloses dosage forms comprising the formulation of inventi...  
WO/2017/163203A1
It is here described a protein which is at least one SUMO protein, or a variant or a fragment thereof or a fusion protein comprising the same for use in the treatment of neurodegenerative and/or neurological disorders. In a further embod...  

Matches 51 - 100 out of 125,990